Shattuck Labs, Inc. (STTK)
NasdaqGS · USD · Healthcare · Biotechnology
$5.54 (+0.91%) as of
Key statistics
- Market cap
- 556.01M
- Forward P/E
- -10.72
- EPS (TTM)
- -0.47
- Dividend yield
- 0.00%
- 52-week range
- 1.72 – 8.33
- Beta
- 1.10
- Revenue (TTM)
- 1M
- Profit margin
- 0.00%
- Analyst target
- $15.40
- Volume
- 706.09k
About Shattuck Labs, Inc.
Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study. It is also involved in the development of various preclinical DR3-based bispecific antibodies for the treatment of patients with inflammatory bowel disease or other immune-mediated indications; and TRIM7, an oncology-focused program. The company was incorporated in 2016 and is headquartered in Austin, Texas.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Austin, TX, United States
- Employees
- 40
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.